Shire, dissatisfied with the success – but not “resounding success” – of its amphetamine/amino acid combination Vyvanse, is developing the drug (which recently failed trials as an antidepressant) as a treatment for binge-eating.
Shire, dissatisfied with the success – but not “resounding success” – of its amphetamine/amino acid combination Vyvanse, is developing the drug (which recently failed trials as an antidepressant) as a treatment for binge-eating.
Oh man. Reading the business press when they report on drugs, especially psych drugs, is like reading the minutes of the latest meeting of Murder, Inc.
Shire, dissatisfied with the success – but not “resounding success” – of its amphetamine/amino acid combination Vyvanse, is developing the drug (which recently failed trials as an antidepressant) as a treatment for binge-eating
Yeah, well they could sell it alongside olanzapine, now there’s a market!
If a drug cannot out-perform placebo (not a difficult task, considering half the data is tossed out); it’s tried for another condition.
And the ones that get approved by the FDA are slightly modified once the cash cow runs dry. They are “re-treaded” and marketed for something else.
Marcia Angell, M.D. –
http://www.youtube.com/watch?v=ouF3ISihHLM
Duane
Wasn’t it recently reported that studies are now showing a connection between stimulant use and obesity and diabetes later in life?